ARMR Sciences
ARMR Sciences, Inc. is a biotechnology company dedicated to ending the fentanyl crisis and defending against synthetic drug threats through American innovation. The company is pioneering scalable, preventative immunotherapies to protect individuals before exposure to lethal synthetic drugs like fentanyl, moving beyond reactive treatments to address the root causes of overdose deaths. ARMR's technology is supported by foundational licenses from the Department of Defense and aligns with federal health and defense agencies. The multidisciplinary team brings significant experience from leading institutions and companies such as MindMed, iBio, Ridgeback Biotherapeutics, Scripps Research, Boston Children’s Hospital, Harvard Medical School, and more. United in their vision to save lives, ARMR is committed to providing lasting protection and solving the overdose crisis for millions in need.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Preclinical preventative immunotherapy candidate for fentanyl-class synthetic opioids
A vaccine-style immunotherapy candidate in preclinical development intended to generate antibodies that bind fentanyl-class molecules to reduce or prevent pharmacologic effects prior to exposure; claims are supported by preclinical animal research and have not been evaluated in humans.
Preclinical preventative immunotherapy candidate for fentanyl-class synthetic opioids
A vaccine-style immunotherapy candidate in preclinical development intended to generate antibodies that bind fentanyl-class molecules to reduce or prevent pharmacologic effects prior to exposure; claims are supported by preclinical animal research and have not been evaluated in humans.
Services
Evaluation and potential provision of investigational products to treating physicians when clinical trials are not an option, subject to applicable law and regulatory approval; includes an initial acknowledgement process and documentation review.
Evaluation and potential provision of investigational products to treating physicians when clinical trials are not an option, subject to applicable law and regulatory approval; includes an initial acknowledgement process and documentation review.
Expertise Areas
- Opioid vaccine development and immunotherapy
- Preclinical in vivo evaluation and safety studies
- Adjuvant discovery and vaccine formulation
- Primary human in vitro and 3D microphysiologic modeling
Key Technologies
- Vaccine immunotherapy platforms
- Adjuvant discovery and formulation platforms
- 3D organotypic/microphysiologic systems
- Primary human cell-based assays
News & Updates
Collin Gage, CEO of ARMR Sciences, discusses the company's focus on safety and transparency in their mission to end the fentanyl crisis.
Bloomberg features ARMR Sciences' efforts to develop a fentanyl vaccine that could help solve opioid drug deaths and overdoses.
Bloomberg covers ARMR Sciences' startup efforts to chemically prevent highs and overdoses from fentanyl with their vaccine.
CBS reports on ARMR Sciences' vaccine for fentanyl overdose as it heads to clinical trial, highlighting its potential to help end fentanyl deaths.
DailyMail discusses ARMR Sciences' groundbreaking fentanyl vaccine and its potential to curb the ongoing epidemic.
Benzinga reports on ARMR Sciences' development of a fentanyl vaccine to prevent fatal overdoses and the company's recent $10M funding.
Collin Gage, CEO of ARMR Sciences, discusses the company's focus on safety and transparency in their mission to end the fentanyl crisis.
Bloomberg features ARMR Sciences' efforts to develop a fentanyl vaccine that could help solve opioid drug deaths and overdoses.
Bloomberg covers ARMR Sciences' startup efforts to chemically prevent highs and overdoses from fentanyl with their vaccine.
CBS reports on ARMR Sciences' vaccine for fentanyl overdose as it heads to clinical trial, highlighting its potential to help end fentanyl deaths.
DailyMail discusses ARMR Sciences' groundbreaking fentanyl vaccine and its potential to curb the ongoing epidemic.
Benzinga reports on ARMR Sciences' development of a fentanyl vaccine to prevent fatal overdoses and the company's recent $10M funding.